Nurexone Biologic Inc
F:J90

Watchlist Manager
Nurexone Biologic Inc Logo
Nurexone Biologic Inc
F:J90
Watchlist
Price: 0.457 EUR 0.22% Market Closed
Market Cap: €30.7m

Nurexone Biologic Inc
Research & Development

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Nurexone Biologic Inc
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
Nurexone Biologic Inc
F:J90
Research & Development
-$1.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Enerflex Ltd
TSX:EFX
Research & Development
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
T
TerraVest Industries Inc
TSX:TVK
Research & Development
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
CES Energy Solutions Corp
TSX:CEU
Research & Development
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Trican Well Service Ltd
TSX:TCW
Research & Development
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Secure Energy Services Inc
TSX:SES
Research & Development
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Nurexone Biologic Inc
Glance View

Market Cap
30.7m EUR
Industry
N/A

NurExone Biologic, Inc. is a pharmaceutical company, which engages in the development and commercialization of biological extracellular vesicles (EV)-based technology drug platform. The company is headquartered in Edmonton, Alberta. The company went IPO on 2012-05-08. The firm is developing a biological extracellular vesicles (EV)-based technology drug platform. The technology drug platform offers treatment for reversing paralysis and improving the life of patients following spinal cord injury using bio-guided exosomes (membrane-bound extracellular vesicles) loaded with modified small interfering RNA (siRNA) sequence. Its technology is used to treat various conditions, such as spinal cord injury, traumatic brain injury, and other brain and neurological indications. The firm also has developed exosome manufacturing process. The company is also focused on exosome research, management of clinical studies and commercialization of the technology for different indications, not limited to the central nervous system.

J90 Intrinsic Value
0.031 EUR
Overvaluation 93%
Intrinsic Value
Price

See Also

What is Nurexone Biologic Inc's Research & Development?
Research & Development
-1.8m USD

Based on the financial report for Dec 31, 2024, Nurexone Biologic Inc's Research & Development amounts to -1.8m USD.

What is Nurexone Biologic Inc's Research & Development growth rate?
Research & Development CAGR 1Y
-20%

Over the last year, the Research & Development growth was -20%.

Back to Top